Aislingke

Aislingke is a Shanghai-based biotechnology company focused on the development of innovative therapies for neurodegenerative diseases, with a primary emphasis on Amyotrophic Lateral Sclerosis (ALS). The company is advancing a pipeline of small molecule candidates designed to address the underlying genetic and protein-folding mechanisms of motor neuron disease. Its lead research efforts involve targeting Superoxide dismutase 1 (SOD1) mutations and other pathological pathways associated with ALS progression. Aislingke collaborates with patient advocacy groups and academic institutions to accelerate the translation of its scientific discoveries into clinical-stage programs. The company aims to provide disease-modifying solutions for conditions with high unmet medical needs in the central nervous system space.